Profile data is unavailable for this security.
About the company
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.
- Revenue in USD (TTM)70.14m
- Net income in USD-76.24m
- Incorporated2002
- Employees174.00
- LocationCodexis Inc200 Penobscot DrREDWOOD CITY 94063-4718United StatesUSA
- Phone+1 (650) 421-8100
- Fax+1 (302) 655-5049
- Websitehttps://www.codexis.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Candel Therapeutics Inc | 0.00 | -37.94m | 264.71m | 42.00 | -- | 20.59 | -- | -- | -1.31 | -1.31 | 0.00 | 0.4381 | 0.00 | -- | -- | 0.00 | -63.82 | -- | -76.57 | -- | -- | -- | -- | -- | -- | -73.91 | 0.6254 | -- | -100.00 | -- | -101.87 | -- | -- | -- |
| Agenus Inc | 156.31m | -245.97m | 265.12m | 389.00 | -- | -- | -- | 1.70 | -13.95 | -13.95 | 8.74 | -8.13 | 0.4297 | -- | 10.94 | 401,832.90 | -70.78 | -55.02 | -194.81 | -115.31 | 98.01 | -- | -164.69 | -102.92 | -- | -1.64 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Actinium Pharmaceuticals Inc | 81.00k | -46.45m | 266.86m | 49.00 | -- | 6.01 | -- | 3,294.56 | -1.72 | -1.72 | 0.003 | 1.49 | 0.0009 | -- | -- | 1,653.06 | -48.80 | -46.98 | -53.25 | -52.71 | -- | -- | -57,346.91 | -6,683.95 | -- | -- | 0.0006 | -- | -92.14 | -- | -47.86 | -- | 9.75 | -- |
| Verastem Inc | 0.00 | -87.37m | 275.85m | 73.00 | -- | 4.80 | -- | -- | -4.07 | -4.07 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -71.39 | -62.70 | -88.82 | -75.18 | -- | -- | -- | -406.17 | -- | -- | 0.3379 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
| Codexis Inc | 70.14m | -76.24m | 276.59m | 174.00 | -- | 3.16 | -- | 3.94 | -1.12 | -1.12 | 1.03 | 1.24 | 0.3625 | 5.43 | 2.31 | 403,120.70 | -39.41 | -17.13 | -50.48 | -20.23 | 81.74 | 77.29 | -108.69 | -37.04 | 2.53 | -- | 0.00 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
| Poseida Therapeutics Inc | 64.70m | -123.43m | 278.18m | 330.00 | -- | 2.65 | -- | 4.30 | -1.38 | -1.38 | 0.7175 | 1.08 | 0.2068 | -- | 7.15 | 196,069.70 | -39.45 | -40.70 | -49.32 | -47.72 | -- | -- | -190.76 | -233.49 | -- | -14.93 | 0.361 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Sanara Medtech Inc | 64.99m | -4.30m | 279.72m | 107.00 | -- | 6.18 | -- | 4.30 | -0.5219 | -0.5219 | 7.85 | 5.25 | 0.9635 | 1.90 | 8.37 | 607,381.70 | -6.58 | -17.73 | -8.17 | -22.07 | 87.92 | 88.08 | -6.83 | -17.13 | 1.04 | -18.75 | 0.1786 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Xeris Biopharma Holdings Inc | 163.91m | -62.26m | 280.20m | 377.00 | -- | -- | -- | 1.71 | -0.4525 | -0.4525 | 1.19 | -0.0491 | 0.4914 | 0.9012 | 4.68 | 434,785.20 | -18.66 | -43.60 | -24.99 | -56.57 | 82.52 | 78.23 | -37.98 | -143.08 | 1.23 | -2.01 | 1.04 | -- | 48.68 | 131.50 | 34.23 | -- | 8.43 | -- |
| Vanda Pharmaceuticals Inc. | 192.64m | 2.51m | 284.01m | 203.00 | 111.29 | 0.5153 | 51.46 | 1.47 | 0.0439 | 0.0439 | 3.35 | 9.47 | 0.3004 | 11.60 | 5.69 | 948,965.50 | 0.3912 | 6.61 | 0.4547 | 7.62 | 92.32 | 90.55 | 1.30 | 15.18 | 4.92 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| Monte Rosa Therapeutics Inc | 0.00 | -135.35m | 284.34m | 133.00 | -- | 1.58 | -- | -- | -2.64 | -2.64 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -41.90 | -- | -47.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Eliem Therapeutics Inc | 0.00 | -35.12m | 284.78m | 9.00 | -- | 2.61 | -- | -- | -1.31 | -1.31 | 0.00 | 3.88 | 0.00 | -- | -- | 0.00 | -28.61 | -- | -29.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Chromadex Corp | 83.57m | -4.94m | 285.48m | 106.00 | -- | 9.96 | -- | 3.42 | -0.0659 | -0.0659 | 1.11 | 0.3795 | 1.53 | 2.25 | 21.38 | 788,396.30 | -9.06 | -42.11 | -14.00 | -65.14 | 60.76 | 59.68 | -5.91 | -30.64 | 1.70 | -- | 0.0008 | -- | 15.99 | 21.50 | 70.15 | -- | -36.66 | -- |
| Akebia Therapeutics Inc | 194.62m | -51.93m | 287.15m | 167.00 | -- | -- | -- | 1.48 | -0.2778 | -0.2778 | 1.04 | -0.1572 | 0.6512 | 2.22 | 4.89 | 1,165,407.00 | -17.37 | -37.42 | -28.19 | -56.00 | 78.76 | 69.13 | -26.68 | -82.25 | 1.03 | -7.64 | 8.46 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| Nektar Therapeutics | 90.12m | -276.06m | 288.29m | 137.00 | -- | 2.29 | -- | 3.20 | -1.46 | -1.46 | 0.4743 | 0.6844 | 0.1626 | 1.91 | 25.08 | 657,824.80 | -49.80 | -31.02 | -55.82 | -34.63 | 62.53 | 78.04 | -306.31 | -372.21 | 6.14 | -21.17 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| XOMA Corp | 4.76m | -46.30m | 288.32m | 13.00 | -- | 3.21 | -- | 60.60 | -4.04 | -4.04 | 0.4148 | 7.72 | -- | -- | -- | 366,000.00 | -- | -4.55 | -- | -4.94 | -- | -- | -858.15 | -31.87 | -- | -- | 0.583 | -- | -21.06 | -2.13 | -105.10 | -- | 23.16 | -- |
| Invivyd Inc | 0.00 | -198.64m | 288.52m | 94.00 | -- | 1.50 | -- | -- | -1.81 | -1.81 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -64.88 | -- | -73.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Codexis Inc's reporting currency: US Dollar USD
45.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.13m | 7.30% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 4.59m | 6.53% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 4.10m | 5.84% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 4.06m | 5.78% |
| Baillie Gifford & Co.as of 31 Dec 2023 | 3.42m | 4.86% |
| Opaleye Management, Inc.as of 31 Dec 2023 | 3.05m | 4.33% |
| Telemark Asset Management LLCas of 31 Dec 2023 | 2.70m | 3.84% |
| Casdin Capital LLCas of 31 Dec 2023 | 2.00m | 2.85% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.51m | 2.15% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.49m | 2.11% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
